Previously unpublished long-term clinical and imaging findings from participants treated with an induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy for chronic ischemic stroke were presented today at the ISSCR 2026 Annual Meeting.
The data include extended follow-up from Phase I studies evaluating hNPC01, an iPSC-derived forebrain neural progenitor cell therapy designed to promote repair of stroke-damaged brain tissue. The findings provide new insight into the long-term safety, feasibility, and biological activity of this regenerative approach in patients living with chronic motor disability following stroke.
"The findings presented at ISSCR 2026 today include previously unpublished long-term clinical and imaging follow-up from participants treated with hNPC01," said Maggie Ho, Ph.D., Hopstem Biotechnology, USA. "These data contribute important information about how an iPSC-derived neural progenitor cell therapy behaves over extended follow-up in patients with chronic stroke and represent an important step in translating regenerative neuroscience into clinical investigation."
Stroke remains one of the leading causes of long-term disability worldwide. While rehabilitation can improve function, patients who have reached the chronic stage of recovery have few treatment options capable of restoring damaged brain tissue or replacing lost neural cells. Regenerative approaches seek to address this unmet need by supporting repair of injured neural tissue and reconstruction of neural networks.
The research addresses one of the central challenges in regenerative medicine for neurological disease. Unlike many tissues, the brain has limited capacity to replace neurons lost after stroke. Any regenerative therapy must demonstrate not only that transplanted cells can survive, but also that they can integrate safely within existing neural circuits over time. Long-term clinical evidence has therefore remained an important objective for the field.
The study enrolled adults who experienced an ischemic stroke between six months and five years before treatment and continued to experience persistent motor disability despite rehabilitation and standard medical care. Participants had stable neurological function before enrollment, allowing investigators to better evaluate changes following transplantation.
According to Ho, one of the most encouraging aspects of the research has been the opportunity to better understand the long-term behavior of transplanted neural progenitor cells through extended clinical and imaging follow-up.
"Long-term observations are essential for advancing regenerative medicine for neurological disease," Ho said. "These findings provide valuable insights into the safety, biological activity, and potential therapeutic impact of neural progenitor cell transplantation while raising important new scientific questions about patient selection, mechanisms of recovery, and how transplanted cells interact with the injured brain over time."
If confirmed in larger controlled clinical trials, regenerative neural cell therapies could expand future treatment options for people living with chronic stroke, a population for whom therapeutic alternatives remain limited. Even modest improvements in motor function have the potential to improve independence and quality of life for patients and their families. However, additional research will be necessary to establish safety and efficacy in larger studies.
The investigators say they are particularly excited to share these findings with the international stem cell community at ISSCR 2026 because long-term clinical evidence remains a critical milestone for the development of regenerative therapies.
"[The] ISSCR brings together the scientists, clinicians, and translational researchers needed to advance this field," said Ho. "We hope these data stimulate discussion, foster new collaborations, and help move regenerative neuroscience toward therapies that can ultimately benefit patients living with chronic neurological disorders."
The researchers plan to continue evaluating hNPC01 in larger controlled clinical studies while investigating the biological mechanisms underlying recovery and optimizing treatment strategies that may maximize long-term benefit for patients.
To learn more about ISSCR 2026 visit www.isscr2026.org
